0000899243-18-026069.txt : 20181003 0000899243-18-026069.hdr.sgml : 20181003 20181003171825 ACCESSION NUMBER: 0000899243-18-026069 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181001 FILED AS OF DATE: 20181003 DATE AS OF CHANGE: 20181003 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Loven Jakob CENTRAL INDEX KEY: 0001753644 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38672 FILM NUMBER: 181105972 MAIL ADDRESS: STREET 1: C/O ARVINAS, INC., 5 SCIENCE PARK STREET 2: 395 WINCHESTER AVENUE CITY: NEW HAVEN STATE: CT ZIP: 06511 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARVINAS INC. CENTRAL INDEX KEY: 0001655759 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472566120 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 395 WINCHESTER COMPANY, LLC STREET 2: 5 SCIENCE PARK CITY: NEW HAVEN STATE: CT ZIP: 06511 BUSINESS PHONE: 203-535-1456 MAIL ADDRESS: STREET 1: 395 WINCHESTER COMPANY, LLC STREET 2: 5 SCIENCE PARK CITY: NEW HAVEN STATE: CT ZIP: 06511 FORMER COMPANY: FORMER CONFORMED NAME: ARVINAS HOLDING COMPANY, LLC DATE OF NAME CHANGE: 20151015 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-10-01 0 0001655759 ARVINAS INC. ARVN 0001753644 Loven Jakob C/O ARVINAS, INC. 5 SCIENCE PARK, 395 WINCHESTER AVE. NEW HAVEN CT 06511 1 0 0 0 Common Stock 2018-10-01 4 P 0 312500 16.00 A 312500 I See Footnote Common Stock 2018-10-01 4 C 0 1381851 A 1694351 I See Footnote Series C Preferred Stock 2018-10-01 4 C 0 4491018 0.00 D Common Stock 1381851 0 I See Footnote Reflects shares of the Issuer's Common Stock that were purchased in connection with the Issuer's initial public offering. The shares are held directly by Nextech V Oncology S.C.S., SICAV-SIF. Nextech V GP S.a r.l. is the general partner of Nextech V Oncology S.C.S., SICAV-SIF. Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a member of the investment committee of Nextech Invest AG and may be deemed to have shared voting and/or investment power over the shares reported hereby. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. On October 1, 2018, the Series C Preferred Stock converted into Common Stock on a 3.25-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. /s/ Matthew Batters, as attorney-in-fact for Jakob Loven 2018-10-03